0001209191-24-000816.txt : 20240104 0001209191-24-000816.hdr.sgml : 20240104 20240104164546 ACCESSION NUMBER: 0001209191-24-000816 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240103 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pizzuti Dana CENTRAL INDEX KEY: 0001948238 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 24512785 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-03 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001948238 Pizzuti Dana C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 0 1 0 0 Chief Med and Dev Officer 1 Common Stock 2024-01-03 4 M 0 14375 16.89 A 20286 D Common Stock 2024-01-03 4 S 0 14375 35.00 D 5911 D Non-qualified stock option (Right to Buy) 16.89 2024-01-03 4 M 0 14375 0.00 D 2032-10-10 Common Stock 14375 206042 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan. The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.00 per share. The range of sales prices on the transaction date was $34.82 to $35.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Marc Wilson 2024-01-04